Entrepreneurship vs. “emprenyadoria”

30 04 2012

(C). Rovira Bassols

Doctor.

The word that best defines start doing one thing, especially when requires effort and work, is to undertake. At the present time, the figure of the entrepreneur, which undertakes, you have purchased a “status” prominent and has become the axis of the majority of the proposals to emerge from the crisis.

However, There is another figure, totally opposed to the first. This figure has a series of characteristics: the discouragement, the distrust, the slander, the lack of talent, destructive criticism, the conspiracy, the absolute lack of initiative… and it is difficult to find a term that defined exactly. The most capable of doing so is perhaps a word in catalan: “l'emprenyador“.

This expression lacks a clear definition and therefore, I have not known how to translate it, but contains various verbs, this can be set using a set of synonyms: teasing, humpback, bother, Badger, incordiar, irritate, enojar, angry, zaherir, tire, fatigue, Dizzy, overwhelm, harass, chinchar, willfulness, load, besiege, moannoyharassing and even envy.

In the video for this article, a leading journalist discusses, humorous, the theme to perfection. He has invented a “formula”, without scientific basis, the composition of any micro-climate and by extension, society itself, in these terms. A 10% consists of entrepreneurs, another 10% are the “emprenyadors” and the 80% remaining, people “you expect”. The 10% entrepreneurs dragged many of the of the 80%, but the 10% of “empemprenyadors221;, also.

A friend of mine, Txema, to see the video, He added a reflection to it that I like to transcribe them: Can do a Manichean division between “emprendedores” -those who are involved and make things- and “emprenyadors” -those who do nothing more than criticizing entrepreneurs-. We can all be “emprendedoentrepreneursd we also can all have one time or another of nonsense “emprenyador”. The enemy is not outside, but inside, for this reason the fight we have to carry out, First of all, against this spoilers all of us and that leads us to immobility and criticise what others do.

In the end, I leave you with the video, It is worth the effort.

Youtube.com [en línea] San Bruno (USA): YouTube.com, 30 April 2012[REF. 2012] Available on Internet: http://www.YouTube.com/watch?v = TyTYf4JTNg



Innovative method to combat Alzheimer's and memory problems.

26 04 2012

And it is that as always we share from Innobk, the innovative and revolutionary ideas need not be associated with major processes of management and investment in r & d. Our country can become a reference in innovation with examples like this. We simply have to change the mentality and move consciences. Difficult task. But examples like this motivate us even more.
Something as simple as a camera, is the instrument that, for the first time in Spain, they are using some neuropsychlogists to help people who do not hold the information in your brain. A method that is also used to combat the symptoms of Alzheimer's disease.

While there is no cure, the investigations that are being carried out in this respect are hopeful. For those who have time, It is really worth seeing this documentary of Eduard Punset.

"With modern diagnostic techniques", "today is possible to detect Alzheimer's before the patient enters the phase of dementia."

Innobk.com [en línea] Barakaldo (ESP): innobk.com, 26 de abril de 2012 [REF. 18 April of 2012] Available on Internet: http://innobk.com/innobk-news/Alzheimer/



Bevacizumab for treating choroidal neovascularisation secondary to pathologic myopia.

23 04 2012

Dres. Bogomil Voykov, Faik Gelisken, Werner Inhoffen, Michael Voelker, Karl Ulrich Bartz-Schmidt & Focke Ziemssen

Graefes Arch Clin Exp RES (2010) 248:543-550

Pathologic myopia is one of the main causes of visual impairment in young adults, around the world. The most important complication is choroidal neovascularisation (NVC) Since the visual acuity of the patients may decrease until 20/200 or less after ten years of follow-up.

Tried several methods to treat it, as laser photocoagulation, extraction of the membrane and foveal translocation. The study of Verteporfin Photodynamic therapy, He showed that such treatment could prevent the loss of vision in patients with CNV secondary to myopia, Although such results will lose statistical significance at the age of two.

Recent reports indicated that the intravitreo administration of anti-VEGF agents: bevacizumab, ranibizumab and pegaptanib, they can inhibit neovascularization and treat it in pathologic myopia.

The present study investigated the effects of monotherapy with intravitreo bevacizumab in patients with CNV secondary to pathologic myopia.

Patients and methods:

Studied a series of consecutive cases, all patients of the Tuebingen Ophthalmic Centre, with two years of follow-up after treatment with 1,25 mg intravitreo bevacizumab alone or in combination with Photodynamic therapy. They studied 21 eyes of 19 patients retrospectively to determine best corrected visual acuity and the thickness of the central fovea.

Follow-up of a patient in the combined group required 21 injections of bevacizumab in total, which shows the difficulty of the treatment of patients with choroidal neovascularisation secondary to myopia.

A. pictures (Photo color) and (b) (fluorescein angiography. AF) They show a choroidal neovascularisation active before starting the combination therapy of photodynamic therapy and bevacizumab. Visual acuity better corrected at this time was 0,3 LogMAR. After this treatment the patient received five injections over because activity persisted in the following 13 months.

Photographs (c) and (d) show the recurrence of choroidal neovascularization. The injection 7 It was carried out without merging with Photodynamic therapy, they needed 4 injections in the following 8 months.

Pictures E and F show still recurrence of the membrane. At this time the visual acuity had fallen to 0,8 LogMAR. It was decided to carry out a new combination therapy and recovered the visual acuity to 0,5 LogMAR and there was no activity of the membrane during the next six months.

The G and H photographs show a third recurrence treated with bevacizumab and Photodynamic therapy (beyond the follow-up period). In the following 15 months only an injection was needed and the patient still being inspected regularly.

There is a treatment generally accepted as satisfactory to treat patients with CNV secondary to pathologic myopia.

In the present study, ten eyes were treated with bevacizumab combined with Photodynamic therapy. This method showed no positive effects after 12 and 24 months.

It is interesting to note that a subgroup of five eyes that were treated for the first time showed a loss of best corrected visual acuity to the 12 months and worsened even more to the 24 months. On the other hand, the other five eyes that had been treated previously with Photodynamic therapy showed an improvement in visual acuity better corrected a year and improved even more at age two.

This is funny, Since it would be expected that a previous treatment and a more long-standing pathology should be a worse result. On the other hand, the early perception of symptoms might have allowed faster treatment of relapses.  These results deserve to be investigated in an essay with the greatest number of cases.

Recently, several studies have shown promising results in the short term treatment with bevacizumab. One of them showed marked differences in visual acuity better corrected after one year of follow-up among patients treated for the first time and those who had previously received Photodynamic therapy.

Another study showed that patients treated with a single session of photodynamic therapy had a better result in visual acuity for those who received several treatment sessions. An explanation for this difference could be atrophy coriorretiniana that develops around the membrane of NVC, Photodynamic therapy can cause side-effects on the coriocapilares, the retina and the retinal pigment epithelium.

In the present study showed a clear trend towards improvement of visual acuity better corrected in the Group of patients treated with bevacizumab for first time. In the combination therapy group, on the other hand the best corrected visual acuity continued equal after two years. Both groups cannot be compared, Since all the eyes of the monotherapy group were treated for the first time.

Yet it could not be determined which is the ideal frequency of injections intravitreo with bevacizumab to treat patients with myopic CNV. Studies with the greatest number of cases should be made to determine which is the best plan of treatment of myopic CNV.

No observed adverse effects in this study, other studies have also shown that the intravitreo bevacizumab is a safe treatment without effects on the retina cytotoxic.

Conclusions:

Despite the limitations in the design of this study, There was combination therapy is superior for treating myopic CNV, at least in terms of functional performance and frequency of injections. The results indicate that bevacizumab may be beneficial in the treatment of patients with CNV secondary to pathologic myopia.

♦ Synthesis and translation: Dr. Martin Mocorrea, editor responsible for Intramed specializing in ophthalmology.

Published: http://www.intramed.net/

Bibliography:
1. Yoshida T, Ohno-Matsui K, K Yasuzumi, Kojima A, Shimada N, Futagami S et al (2003) Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110(7):1297–1305
2. Ohno-Matsui K, Yoshida T (2004) Myopic choroidal neovascularization:
natural course and treatment. Curr Opin Ophthalmol 15 (3):197–202
3. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H et al (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial–VIP report no. 3. Ophthalmology 110(4):667–673
4. Potter MJ, Szabo SM, Ho T (2006) Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal eovascularization in a 13-year-old girl. Graefes Arch Clin Exp RES 244(5):639–641
5. Marticorena J, Gomez-Ulla F, Fernandez M, Pazos B, Rodriguez-Cid MJ, Sanchez-Salorio M (2006) Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularisation. Am J Ophthalmol 142(2):335–337
6. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS (2007) Combined photodynamic therapy and triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. BR j RES 91(2):131-133

Miopiamagna.blogspot.com.es [en línea] (ESP): miopiamagna.blogspot.com.es, 23 de abril de 2012 [REF. 21 April of 2012] Available on Internet: http://miopiamagna.blogspot.com.es/2012/04/10-Ene-11-miopia-bevacizumab-para.html



X-rays shed new light on lung function

19 04 2012

A new technique for assessing lung function using x-rays has been developed by Australian researchers.

This may enable earlier detection of lung diseases such as cancer, emphysema and asthma, and lead to more effective treatments for these conditions.

Biological engineer Stephen Dubsky and colleagues at Monash University in Melbourne report their findings today in the Journal of the Royal Society Interface.

The new method uses an x-ray source to make movies of the breathing lung (Source: Stephen Dubsky, Stuart Hooper, Karen Siu and Andreas Fouras)

The new method uses an x-ray source to make movies of the breathing lung (Source: Stephen Dubsky, Stuart Hooper, Karen Siu and Andreas Fouras)

Currently, doctors typically assess lung health by using flow meters that measure the volume of air exhaled. However, flow meters can’t identify if only a small part of the respiratory system is affected by disease, as in the early stages of cancer.

The new method, created by Dubsky and his team, is called 4D imaging and uses an x-ray source to make movies of the breathing lung, allowing scientists to study lung function in unprecedented detail.

“We are the first team to measure airflow within the lung,” says Andreas Fouras, biomedical engineer and senior author of the paper.

In their study, researchers used 4D imaging to assess lung motion in rabbit pups and mice. There are more than 100 airways inside the body and this technique was able to measure flow throughout the airway tree. It was also effective at measuring other variables such as the elasticity and expansion of lung tissue.

New insight into lung diseases

Dubsky explains that with this extra information, diseases such as lung cancer can be detected much earlier; giving doctors a better opportunity to treat patients and potentially save lives.

He adds that it is also useful for monitoring the progress of medical treatments and conducting research into respiratory diseases such as asthma.

“We can use this new technology to better understand asthma and tailor the treatment to the patient,” says Dubsky.

But is 4D imaging safe for use on humans?

Fouras says that in a previous study the research team discovered how to lower the x-ray doses for the imaging process.

The team is now working to implement this technology into a human clinical scanner. This would result in a smaller and safer amount of radiation exposure than is emitted by current technologies such as CT scans.

The research team is excited about the prospect of applying their 4D imaging technique to human patients. They estimate that a prototype will be available within five years.

“This could have a really valuable impact on society,” says Dubsky.

Abc.net.au [en línea] Sydney (AUS): ABC.NET.au, 19 April 2012[REF. 04 April of 2012] Available on Internet:http://www.ABC.NET.au/science/articles/2012/04/04/3470282.htm

Related article: http://www.flair.monash.edu.au/publications/pdfs/Dubsky_PIV11_Paper.pdf



ELSEVIER revolutionizes medical searches online with ClinicalKey

16 04 2012

This week the medical Publisher ELSEVIER has presented, first in United States and then in London, ClinicalKey, a new online medical search engine that offers faster, comprehensive and proven information on clinical data to medical specialists.

How to get a medical diagnosis in less than six minutes?? That is the great challenge of many medical specialists, that in the majority of cases you have a short time in a query to obtain a clear and accurate diagnosis. In six minutes, it is very difficult that a physician may have contrasting opinions of colleagues, or even the possibility of consulting books or reference articles. If add to this I the role increasingly more active patients in making decisions about your health, a diagnosis or treatment can become a test for the doctor.

Unlike other search engines Online used by medical specialists to search for information on medical consultations, as the popular search engine ‘up to date‘, the most relevant results in a search - how do search engines like Yahoo or Google - are not obtained in ClinicalKey, but the more relevant results and ‘ contextualized ’. From ELSEVIER They stress that this feature of ‘ searches taxomizadas’ is exclusive to ClinicalKey.

This new search engine Online, This includes not only the international publications of the group information ELSEVIER, but many other health reference publications, It has been available for a few months in a beta version for doctors and librarians of the different national systems of health of several countries, among them Spain. Like this, more than 2.000 doctors have seen how ‘ ClinicalKey reduces the time the diagnosis and thus, devote more time to the attention to the patient ’,They claim from ELSEVIER.

During the presentation of ClinicalKey at the top of the Altitude building 360 in London, the CEO of ELSEVIER, Michael Hansen, It has stressed that ‘ physicians want to access information quickly, and get quick answers’. In this sense, the search engine developer, Jim Donohue, He pointed out that this new search engine allows you to ‘ provide information faster, and serve the people in less time’, and it is that this expert is clear to ensure that ‘ if we give good information, We improve the health of our patients’.

The social network of ClinicalKey

ClinicalKey not only is a tool for searching medical Online, It also offers the possibility to contact the thousands of users around the world who make use of it. Through various forums of clinical specialties, doctors can compare information.

Prnoticias.com [en línea] Madrid (ESP): prnoticias.com, 16 de abril de 2012 [REF. 14 April of 2012] Available on Internet: http://www.prnoticias.com/index.php/Salud/1115/20113393



Novartis launches the encyclopedia of Cancerosas cell lines (CCLE, for its acronym in English) to classify the cancer cell lines in the world

12 04 2012

Collaboration with the Broad Institute has resulted in a comprehensive encyclopedia with the genetic and molecular information about of 1.000 cancer cell lines. 

The encyclopedia, available to the public, It could improve the design of the studies on cancer and allow progress in your research.

Data from the encyclopedia could help researchers identify patients who could get the most benefit from a particular drug.

 

Novartis and the Broad Institute have developed an encyclopedia of cancer cell lines which classifies the genetic and molecular profiles of nearly 1.000 human cancer cell lines used in research and development of drugs. The results of the collaboration, published in the magazine Nature and disclosed in advance on the internet [1], they could allow the use of this information to improve the design of the trials against cancer and advance their research scientists from around the world.

“Cancer is a genetic disease. Cell lines reflect genetic changes that cause cancers. Explore cell lines with drugs targeting specific pathways, as has been done for the encyclopedia of Cancer cell lines, It provides a powerful tool for the design of the treatment of cancer,” said Mark Fishman, President of the Novartis Institutes for biomedical research (NIBR, for its acronym in English). “We make this information available to the public yesperamos that many researchers and other people in the industry to use these data to discover new targets for drugs, in order to assess current therapies and to facilitate the treatment of patients with cancer.”

Genetic and molecular cell lines profiles data are available free of charge to the scientific community in the the Broad Institute website .

Researchers used cell lines to shed light on how patients could better use the already existing or new drugs. “Without access to a set of molecular data systematically collected, researchers can not relate to experiments of the cell lines with tumors of the patients when they are available new drugs,” said William Sellers, Global Director of Oncology, NIBR. “The encyclopedia of stem cell cancer will provide scientists the ability to build predictive models with the types of patients who will respond to a particular type of drugs.

The cell lines were acquired from U.S. commercial distributors.UU, Europe, Japan and Korea represent the wide variety of cancer as a disease, since they include various subtypes of common forms of cancer both how little common. According to the main authors and researchers of the NIBR, Jordi Barretina and Giordano Caponigro, each cell line characterized genetically through a series of great performance at the Broad Institute analysis, including the global patterns of expression of RNA, changes in the number of copies of the DNA, as well as variations in the sequence of DNA in close of 1.600 cancer-associated genes, and pharmacological profiles of various drugs in about half of the cell lines. Algorithms have been developed to predict responses to drugs based on genetic and molecular composition of cancer cells.

Pair this information with forms of genotyped quickly samples of tumours of patients represents the next step in the effort to allow the customization of cancer treatment. Some important researchers hospitals already perform a routine genetic profile of the tumors of cancer patients and it is likely that many more follow them, According to researchers.

This release contains certain information in advance about the future, concerning the company's business. There are factors that may affect actual results.

Pmfarma.com.MX [en línea] Barcelona (ESP): pmfarma.com.MX, 12 de abril de 2012 [REF. 02 April of 2012] Available at http://www.pmfarma.com.MX/Noticias/6598-Novartis-Lanza-la-Enciclopedia-de-Lineas-celulares-cancerosas-CCLE-por-SUS-Siglas-en-Ingles-para-clasificar-Las-Lineas-celulares-cancerig.html



Researchers at Harvard completo Wyss Institute Develop DNA Nanorobot to Trigger Targeted Therapeutic Responses

9 04 2012

The programmable DNA nanorobot was modeled on the body's own immune system in which white blood cells patrol the bloodstream for any signs of trouble. [Image created by Campbell Strong, Shawn Douglas, and Gaël McGill using Molecular Maya and cadnano.]

The programmable DNA nanorobot was modeled on the body’s own immune system in which white blood cells patrol the bloodstream for any signs of trouble. [Image created by Campbell Strong, Shawn Douglas, and Gaël McGill using Molecular Maya and cadnano.

Novel technology could potentially seek out cancer cells and cause them to self-destruct.

BOSTON, MA — Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have developed a robotic device made from DNA that could potentially seek out specific cell targets within a complex mixture of cell types and deliver important molecular instructions, such as telling cancer cells to self-destruct. Inspired by the mechanics of the body’s own immune system, the technology might one day be used to program immune responses to treat various diseases. The research findings appear in today’s issue of Science.

 

Using the DNA origami method, in which complex three-dimensional shapes and objects are constructed by folding strands of DNA, Shawn Douglas, Ph.D., a Wyss Technology Development Fellow, and Ido Bachelet, Ph.D., a former Wyss Postdoctoral Fellow who is now an Assistant Professor in the Faculty of Life Sciences and the Nano-Center at Bar-Ilan University in Israel, created a nanosized robot in the form of an open barrel whose two halves are connected by a hinge. The DNA barrel, which acts as a container, is held shut by special DNA latches that can recognize and seek out combinations of cell-surface proteins, including disease markers. When the latches find their targets, they reconfigure, causing the two halves of the barrel to swing open and expose its contents, or payload. The container can hold various types of payloads, including specific molecules with encoded instructions that can interact with specific cell surface signaling receptors.

Douglas and Bachelet used this system to deliver instructions, which were encoded in antibody fragments, to two different types of cancer cells — leukemia and lymphoma. In each case, the message to the cell was to activate its “suicide switch” — a standard feature that allows aging or abnormal cells to be eliminated. And since leukemia and lymphoma cells speak different languages, the messages were written in different antibody combinations.

This programmable nanotherapeutic approach was modeled on the body’s own immune system in which white blood cells patrol the bloodstream for any signs of trouble. These infection fighters are able to home in on specific cells in distress, bind to them, and transmit comprehensible signals to them to self-destruct. The DNA nanorobot emulates this level of specificity through the use of modular components in which different hinges and molecular messages can be switched in and out of the underlying delivery system, much as different engines and tires can be placed on the same chassis. The programmable power of this type of modularity means the system has the potential to one day be used to treat a variety of diseases.

“We can finally integrate sensing and logical computing functions via complex, yet predictable, nanostructures — some of the first hybrids of structural DNA, antibodies, aptamers and metal atomic clusters — aimed at useful, very specific targeting of human cancers and T-cells,” said George Church, Ph.D., a Wyss core faculty member and Professor of Genetics at Harvard Medical School, who is Principal Investigator on the project. Because DNA is a natural biocompatible and biodegradable material, DNA nanotechnology is widely recognized for its potential as a delivery mechanism for drugs and molecular signals. But there have been significant challenges to its implementation, such as what type of structure to create; how to open, close, and reopen that structure to insert, transport, and deliver a payload; and how to program this type of nanoscale robot.

By combining several novel elements for the first time, the new system represents a significant advance in overcoming these implementation obstacles. For instance, because the barrel-shaped structure has no top or bottom lids, the payloads can be loaded from the side in a single step–without having to open the structure first and then reclose it. Also, while other systems use release mechanisms that respond to DNA or RNA, the novel mechanism used here responds to proteins, which are more commonly found on cell surfaces and are largely responsible for transmembrane signaling in cells. Finally, this is the first DNA-origami-based system that uses antibody fragments to convey molecular messages — a feature that offers a controlled and programmable way to replicate an immune response or develop new types of targeted therapies.

“This work represents a major breakthrough in the field of nanobiotechnology as it demonstrates the ability to leverage recent advances in the field of DNA origami pioneered by researchers around the world, including the Wyss Institute’s own William Shih, to meet a real-world challenge, namely killing cancer cells with high specificity,” said Wyss Institute Founding Director, Donald Ingber, M.D., Ph.D. Ingber is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Children’s Hospital Boston, and Professor of Bioengineering at Harvard’s School of Engineering and Applied Sciences. “This focus on translating technologies from the laboratory into transformative products and therapies is what the Wyss Institute is all about.”

For more information, contact Mary Tolikas

mary.tolikas@wyss.harvard.edu

 

About the Wyss Institute for Biologically Inspired Engineering at Harvard University
The Wyss Institute for Biologically Inspired Engineering at Harvard University (http://wyss.harvard.edu) uses Nature’s design principles to develop bioinspired materials and devices that will transform medicine and create a more sustainable world. Working as an alliance among Harvard’s Schools of Medicine, Engineering, and Arts & Sciences, and in partnership with Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Children’s Hospital Boston, Dana Farber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, Spaulding Rehabilitation Hospital, and Boston University, the Institute crosses disciplinary and institutional barriers to engage in high-risk research that leads to transformative technological breakthroughs. By emulating Nature’s principles for self-organizing and self-regulating, Wyss researchers are developing innovative new engineering solutions for healthcare, energy, architecture, robotics, and manufacturing. These technologies are translated into commercial products and therapies through collaborations with clinical investigators, corporate alliances, and new start-ups.

Wyss.Harvard.edu [en línea] Boston (USA): wyss.harvard.edu, 09 April of 2012 [REF. 16 de febrero de 2012] Available on Internet:http://Wyss.Harvard.edu/viewpressrelease/75/



The inclusion of a ring in the womb reduces in a 75 percent premature births

5 04 2012
Fotografía facilitada por el Hospital Universitario Vall d'Hebron del anillo de silicona …

Photography provided by the Hospital Universitario Vall d ’ the silicone ring Hebron...

Barcelona, 3 Apr (EFE).- A test carried out in the Hospital Vall d ’ Hebron It has been shown that the placement of a ring of silicone in the uterus, introduced by the vagina, reduces in a 75 percent premature births at risk pregnancies.

The study, It publishes the British magazine today “The Lancet“, It has proven the effectiveness of this silicone ring, also known as a pessary, on a sample of 15.000 women who had in common a short cervix (length of 25 mm), What is a risk factor for preterm birth.

Used pessary costs 38 EUR, is introduced through the vagina without surgery and does not produce discomfort or side effects.

“It is an extremely simple and cheap system”, highlighted today EfE the head of the unit of medicine fetal from the service of obstetrics of the Vall d ’ Hebron and coordinator of the study, Elena careers.

Preterm birth (before the 34 weeks of gestation), that occurs in a 8 percent of the cases in Spain, It is the leading cause of serious illness and mortality of the newborn.

To reduce this rate of prematurity enough with that public health expand ultrasound to the vaginal area of the 20 weeks of gestation to, by system, practice all pregnant.

The women who have short cervix unknown it because this malformation does them no discomfort and are only detected by ultrasound.

“The health system has to do this small effort, that will prevent many preterm births that, in the long run, they generate a lot more spending”, highlighted careers.

The pessary is inserted bent by the vagina and, Once deployed in the array, acts as a stopper, What prevents the fetus is orientated towards the vagina and forces him to return to the normal position.

A week 37 gestation, the ring is removed through the vagina so that women can give birth normally.

In the study, that has received funding from the Instituto de Salud Carlos III, they have collaborated with the contribution of each 400 patients of other five Spanish centers: The Hospital de Fuenlabrada (Madrid), the mother and child of Las Palmas de Gran Canaria, the Son Llatzer in Palma de Mallorca, of Sant Joan de Reus (Tarragona) and the Institute Dexeus of Barcelona.

Pessaries made them disabled the German NGO Clara-Angela - Foundation of Dr. Birgit Arabin, who, in 2003, He made the first studies about the benefits of these rings, Although it has not been until now that they have been tested in a randomized study large scale.

es.noticias.yahoo.com [en línea] Madrid (ESP): ES.noticias.Yahoo.com, 5 de abril de 2012 [REF. 3 April of 2012] Available on Internet:http://ES.noticias.Yahoo.com/insercion-anillo-utero-reduce-75-ciento-partos-prematuros-022200633.HTML



Dr KERDEL-VEGAS: DO YOU CAN CURE ALZHEIMER'S DISEASE??

2 04 2012

Francisco Kerdel-Vegas

Francisco.kerdelvegas@gmail.com

www.bitacoramedica.com

With the gradual increase in global life expectancy, It is logical to proportionally increase degenerative diseases observed especially in the elderly, such as cancer and Alzheimer's disease (EA).

Alzheimer's disease (It is named for German neuropathologist and psychiatrist, Alois Alzheimer, who described it in 1906), It is recognized as the most common form of dementia. Far is not known to be an effective treatment for this disease, It gets worse when you progress over time and eventually leads to the death of the patient (on average about seven years after its inception).

It was estimated that you for the year 2006 had 26,6 million patients worldwide and that already substantial number will continue to grow with an annual levy disproportionate in the following years. In the United States alone it is estimated that you there are more than 5 millions of patients with EA.

At the beginning of this frightening disease's own cognitive disorders, that usually affects men and women of 65 years, It manifests itself by the difficulties experienced to remember recent events. Then the behavior of the patient is complicated and the symptoms appear confusion, irritability, aggression, sudden mood changes, problems talking and distant memory loss. As these symptoms are established, the patient with EA distances himself from the family and social life, and an almost permanent assistance required.

More than one year ago said that, “the statistics are incontrovertible, the disease has become the number one public health of the United States problem by their frequency and their havoc. Before that nothing is to be noted that he has acquired the characteristics of an epidemic, Since produces the death of 5,3 millions of citizens of that country in a year, and undertake economic activity of 11 millions more, dedicated to caring for the sick. The cost is astronomical and reaches more of 170 billions of dollars per year, with a projection of reach to 2 trillions of dollars in the next decade.” (DOCTOPOLIS blog).

The information released this month of February of 2012 in the prestigious magazine Science, by the Group of neuroscientists at Case Western Reserve University (Cleveland, Ohio), led by Professor Gary Landreth, It reveals the remarkable improvement in three varieties of mice with induced EA, under treatment with Bexarotene. This drug, whose trade name is Targretin, is a molecule that is approved by the “Food and Drug Administration” (FDA) the year 2000 for treatment of cutaneous T-cell lymphoma, It was developed by Ligand Pharmaceuticals (San Diego, California) and whose rights were subsequently acquired by the Japanese pharmaceutical House Eisai in 2006.

Although we must admit that the cause and progression of the EA still produce many unknowns, numerous studies show that it is associated with the tank in the brain of plaques and tangles of amyloid, and Landreth explained that the Bexarotene acts increasing levels of apolipoprotein E, that helps eliminate the amyloid plaques.

It is, without doubt, a momentous discovery and has been well received by distinguished scientists in all parts of the world, and although test results obtained with the Bexarotene in the EA in mice can be played in humans it will take some time (perhaps even years), in the case of a drug already approved and used in the treatment of other conditions, It is not difficult to deduce that sooner rather than later we know how effective is human.